Peptide Schedule
Bromantane (Ladasten)Small moleculeNo amino acid sequence. Icon reflects category theme only.Bromantane (Ladasten)
Benefits
About Bromantane (Ladasten)
Bromantane (N-(4-bromophenyl)adamantan-2-amine) is a synthetic actoprotector developed at the Russian Academy of Medical Sciences during the late 1980s. It's built on an adamantane scaffold — the same bicyclic carbon cage found in amantadine and memantine — with a brominated aniline group attached. This structural hybrid gives it a pharmacological profile that doesn't fit neatly into any single drug class: it's simultaneously a mild psychostimulant, an anxiolytic, and a physical performance enhancer. The compound first surfaced publicly after several athletes at the 1996 Atlanta Olympics tested positive for it. At that point, bromantane wasn't on the IOC's banned substance list, so those results were initially controversial. WADA later added it to the Prohibited List as a specified stimulant (category S6), where it remains today. What makes bromantane unusual is its mechanism. Unlike amphetamines or modafinil, it doesn't block dopamine reuptake or flood synapses with monoamines. Instead, it works through indirect genomic regulation — upregulating the expression of tyrosine hydroxylase (TH) and aromatic L-amino acid decarboxylase (AAAD), the two rate-limiting enzymes in dopamine biosynthesis. A single dose can produce a 2- to 2.5-fold increase in TH expression in the hypothalamus within 1.5 to 2 hours. The downstream result is a gradual, sustained increase in dopamine synthesis rather than a sudden spike and crash. Bromantane's anxiolytic effects appear to operate through a separate pathway involving GABA-ergic mediation, which is why users often describe it as providing calm focus rather than the jittery stimulation typical of conventional stimulants. There's also evidence it increases brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) expression in certain brain regions. Russia approved bromantane under the brand name Ladasten around 2009 for treating neurasthenia (chronic fatigue with cognitive complaints). A large multicenter trial involving 728 patients showed 90.8% improvement on the CGI-I scale at doses of 50-100 mg daily over 28 days, with adverse effects in only 3% of patients. That said, Western clinical data is extremely limited — there are no FDA-reviewed trials, no double-blind placebo-controlled studies published in English-language journals of the caliber you'd expect for a prescription drug, and most pharmacological data comes from Russian-language publications or preclinical animal work.
Who Should Consider Bromantane (Ladasten)
- Adults seeking non-stimulant cognitive and motivational support (research context)
- Individuals with neurasthenia or chronic asthenic conditions (approved in Russia)
- Researchers studying dopamine biosynthesis upregulation mechanisms
- Those investigating anxiolytic compounds without benzodiazepine-class risks
- Athletes subject to WADA testing should NOT use — bromantane is a banned substance
How Bromantane (Ladasten) Works
Bromantane's primary action is indirect genomic upregulation of dopamine biosynthesis. It increases transcription of tyrosine hydroxylase (TH) mRNA and protein in the hypothalamus, striatum, ventral tegmental area, and nucleus accumbens. It also upregulates aromatic L-amino acid decarboxylase (AAAD), which converts L-DOPA into dopamine. Together, these enzyme increases lead to enhanced dopamine production and release without the reuptake inhibition or vesicular dumping seen with traditional stimulants. The timeline of this effect is notable: TH upregulation appears within 1.5-2 hours of a single oral dose and produces a 2-2.5 fold increase in enzyme expression. This genomic mechanism explains why bromantane's effects build gradually and persist well beyond what plasma half-life alone would predict. It also explains the low abuse potential — there's no immediate dopamine surge, just a steady upward shift in baseline synthesis capacity. On the anxiolytic side, bromantane strengthens GABA-ergic neurotransmission. The exact molecular target hasn't been fully characterized, but it doesn't appear to act directly on GABA-A benzodiazepine binding sites. This gives it anxiolytic properties without the sedation, cognitive impairment, or dependence risk associated with benzodiazepines. Bromantane also shows serotonergic activity and has been found to increase expression of neurotrophins including BDNF and NGF in certain rat brain areas. These neurotrophic effects could contribute to the cognitive improvements reported with longer-term use, though human data confirming this is sparse. Pharmacologically, bromantane is highly lipophilic. It distributes extensively into adipose tissue and brain, which accounts for its large volume of distribution and the detection of its primary metabolite (6-beta-hydroxybromantane) in urine for up to two weeks after a single dose. Oral bioavailability is approximately 42%, with significant first-pass hepatic metabolism. Peak plasma concentration is reached at roughly 2.75 hours in females and 4 hours in males.
What to Expect
Subtle effects may begin within hours of the first dose as TH upregulation kicks in. Most users report a gentle lift in mood and motivation without obvious stimulation. Some notice reduced background anxiety. Effects are mild as the genomic mechanism is still ramping up.
Dopamine synthesis upregulation reaches meaningful levels with consistent daily dosing. Users typically report improved focus, mental clarity, and a sense of calm drive. Physical stamina may start to improve. The combination of stimulant and anxiolytic effects becomes more apparent.
Peak effects for most users. Sustained improvements in motivation, cognitive stamina, and stress tolerance. Some report improved verbal fluency and task initiation. Physical endurance benefits are more noticeable. BDNF-related neuroplasticity effects may begin contributing.
Final week of a standard cycle. Benefits should be well-established. Begin planning the off-cycle period. Some users taper to 25-50 mg for the last few days rather than stopping abruptly, though there's no clinical data mandating a taper.
Effects taper gradually over 3-7 days due to tissue accumulation. Metabolites remain detectable in urine for up to two weeks. Most users don't report a significant rebound or withdrawal. Maintain any cognitive habits or routines established during the cycle.
Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 25mg | Daily |
| Moderate | 50mg | Daily |
| Aggressive | 100mg | Daily |
Note: Oral compound — no reconstitution needed. Taken as capsule, tablet, or sublingual powder. Not a peptide but commonly sold in the same market. Approved in Russia as Ladasten for neurasthenia; not FDA-approved. Banned by WADA as a stimulant. Cycle 4 weeks on, 2-4 weeks off.
How to Inject Bromantane (Ladasten)
Take orally in the morning or early afternoon. Avoid evening dosing as the 8-12 hour duration of effects may interfere with sleep. Can be taken with or without food, though a small fatty meal may improve absorption given its lipophilic nature. Start at 25-50 mg daily for the first week to assess tolerance before moving to 50-100 mg. Sublingual administration of powder is reported to have faster onset but no formal bioavailability data exists for this route. Do not exceed 100 mg daily without medical supervision.
Cycling Protocol
Standard cycling is 4 weeks on at 50-100 mg daily, followed by 2-4 weeks off. Some users run shorter 2-week cycles. Due to lipophilic accumulation in adipose tissue, taking breaks is important even though acute tolerance doesn't appear to develop. The Russian clinical trial used a 28-day continuous dosing protocol. Avoid stacking with other dopaminergic compounds during use.
Pharmacokinetics
Source: Reported pharmacokinetic half-life of approximately 11.21 hours for the parent compound. Metabolites (primarily 6-beta-hydroxybromantane) detectable in urine for up to 2 weeks due to slow release from adipose tissue storage. Oral bioavailability ~42%.
Loading the interactive decay curve.
Side Effects
Generally well-tolerated at 50-100 mg daily based on Russian clinical data (adverse events in ~3% of 728-patient trial). Reported side effects include mild headache, GI discomfort, insomnia if taken too late in the day, and occasional dry mouth. At higher doses or with prolonged use: potential hepatic strain due to lipophilic accumulation, mild increases in anxiety (paradoxical in some users), and skin rash. Bromantane accumulates in adipose tissue due to its high lipophilicity, so metabolites can be detected in urine for up to two weeks after a single dose. Long-term safety data from controlled trials is essentially nonexistent outside of Russian-language literature.
Contraindications
- Pregnancy or breastfeeding — no reproductive safety data in humans
- Children and adolescents under 18 — not studied in pediatric populations
- Severe hepatic impairment — bromantane undergoes extensive hepatic metabolism and is highly lipophilic
- Known hypersensitivity to adamantane-class compounds (amantadine, memantine, rimantadine)
- Active psychotic disorders — dopamine upregulation could theoretically worsen symptoms
- Competitive athletes subject to WADA testing — bromantane is a specified stimulant on the Prohibited List (S6)
- Concurrent use of MAO inhibitors — potential for excessive dopaminergic activity
Drug Interactions
- MAO inhibitors (selegiline, phenelzine, tranylcypromine) — bromantane increases dopamine synthesis; combined with MAO inhibition this could produce excessive dopaminergic stimulation
- Levodopa/carbidopa — additive dopamine-enhancing effects; monitor for signs of dopamine excess (agitation, insomnia, dyskinesia)
- Dopamine agonists (pramipexole, ropinirole) — potential for additive dopaminergic stimulation
- Benzodiazepines — bromantane has GABA-ergic effects that may potentiate sedation at higher doses, though at normal doses the interaction is likely minimal
- CYP450 substrates — bromantane undergoes hepatic hydroxylation; potential for competition with drugs metabolized by the same enzymes (specific CYP isoforms not fully characterized)
- Other stimulants (caffeine, modafinil, amphetamines) — stacking with bromantane may overshoot dopaminergic tone; use caution
Storage & Stability
Related Peptides
References
- The effects of ladasten on dopaminergic neurotransmission and hippocampal synaptic plasticity in rats (Neuropharmacology 2008)PubMed 17854844
- Ladasten, a new drug with psychostimulant and anxiolytic actions in treatment of neurasthenia — results of comparative clinical study with placebo (Zh Nevrol Psikhiatr 2009)PubMed 19491814
- Treatment of asthenic disorders in patients with psychoautonomic syndrome: results of a multicenter study on efficacy and safety of ladasten (Zh Nevrol Psikhiatr 2011)PubMed 21322821
- The Pharmacology of Actoprotectors: Practical Application for Improvement of Mental and Physical Performance (Int J Sport Nutr Exerc Metab 2010)PubMed 24347315
- Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA) (Br J Pharmacol 2008)PubMed 18500382